Dare Bioscience, Inc. (NASDAQ:DARE) Short Interest Update

Dare Bioscience, Inc. (NASDAQ:DARE) was the recipient of a significant drop in short interest in the month of January. As of January 30th, there was short interest totaling 310,398 shares, a drop of 14.1% from the January 15th total of 361,373 shares. Currently, 2.3% of the shares of the company are sold short. Based on an average daily volume of 79,738 shares, the short-interest ratio is presently 3.9 days. Based on an average daily volume of 79,738 shares, the short-interest ratio is presently 3.9 days. Currently, 2.3% of the shares of the company are sold short.

Analyst Ratings Changes

Several research firms have recently commented on DARE. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Dare Bioscience in a report on Tuesday, December 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Dare Bioscience in a report on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $10.00.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Raymond James Financial Inc. grew its holdings in Dare Bioscience by 810.6% during the 3rd quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 13,650 shares during the last quarter. LPL Financial LLC acquired a new stake in shares of Dare Bioscience during the fourth quarter valued at $28,000. Virtu Financial LLC acquired a new stake in shares of Dare Bioscience during the third quarter valued at $37,000. Finally, AMH Equity Ltd increased its position in Dare Bioscience by 17.8% during the 2nd quarter. AMH Equity Ltd now owns 193,603 shares of the biotechnology company’s stock worth $463,000 after purchasing an additional 29,301 shares in the last quarter. 6.70% of the stock is currently owned by institutional investors and hedge funds.

Dare Bioscience Trading Down 1.2%

Shares of DARE stock opened at $1.65 on Thursday. The stock has a market cap of $23.58 million, a P/E ratio of -0.88 and a beta of 0.93. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.06. Dare Bioscience has a fifty-two week low of $1.61 and a fifty-two week high of $9.19. The business has a fifty day simple moving average of $1.95 and a 200-day simple moving average of $1.99.

About Dare Bioscience

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.